Juan Alarcon, MD
Urology · Montebello, CANPI 1609834217
Payments from drug & device makers
What this record shows
This record is dominated by education: $19,706 of the $27,262 with a category attached, or 72.3%. Coloplast accounts for 73.0% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2020 at $12,724 and has fallen 90.7% since, to $1,180 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $93.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$20K
- Pfizer$947
- SN Holdings, LLC$868
- Astellas Pharma US Inc$802
- Sumitomo Pharma America, Inc.$646
- Myriad Genetic Laboratories, Inc.$588
- plus $3K from 27 others
Across 2 payments — averaging $15,134 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$30K
What the payments were for
- Grants$1210%
- Travel & lodging$4352%
- Food & beverage$7,00026%
- Education$19,70672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 46 | $19,913 |
| Pfizer | 44 | $947 |
| SN Holdings, LLC | 2 | $868 |
| Astellas Pharma US Inc | 34 | $802 |
| Sumitomo Pharma America, Inc. | 27 | $646 |
| Myriad Genetic Laboratories, Inc. | 18 | $588 |
| Johnson & Johnson | 23 | $560 |
| Teleflex LLC | 17 | $504 |
| Bayer | 12 | $314 |
| Dornier Medtech America, Inc | 1 | $258 |
| Neotract Inc. | 9 | $214 |
| Procept Biorobotics Corporation | 3 | $206 |
| Convatec Inc. | 7 | $199 |
| Calyxo, Inc. | 2 | $166 |
| Medtronic | 3 | $154 |
| Accord Healthcare, Inc. | 7 | $148 |
| Boston Scientific | 6 | $136 |
| Urovant Sciences Inc | 6 | $121 |
| Myovant Sciences Inc. | 4 | $101 |
| Antares Pharma, Inc. | 4 | $68 |
| Axonics, Inc. | 2 | $46 |
| Dendreon Pharmaceuticals LLC | 2 | $45 |
| Progenics Pharmaceuticals, Inc. | 2 | $39 |
| Amgen | 1 | $33 |
| Novartis | 1 | $32 |
| AbbVie | 1 | $28 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $27 |
| Urogen Pharma, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Halozyme Inc | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
| Rigicon,inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$19,024
- XTANDI$496
- Consumables & Accessories$258
- Prolaris$154
- CVAC Aspiration System$146
- AQUABEAM SYSTEM$139
How this compares
$27,262 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 45 | $721,538 |
| Lupron DepotLeuprolide Acetate | 61 | $703,858 |
| GemtesaVibegron | 289 | $240,925 |
| MyrbetriqMirabegron | 144 | $112,674 |
| Tamsulosin Hcl | 1,491 | $27,553 |
| Finasteride | 933 | $12,517 |
| Silodosin | 12 | $2,429 |
| Dutasteride | 52 | $2,204 |
| Oxybutynin Chloride | 156 | $1,757 |
| Bicalutamide | 41 | $1,645 |
| Oxybutynin Chloride ErOxybutynin Chloride | 70 | $1,535 |
| Ciprofloxacin Hcl | 575 | $1,456 |
| Solifenacin Succinate | 12 | $1,352 |
| Estradiol | 25 | $1,208 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 30 | $663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $802 | $834,212189 claims |
| AbbVieLupron Depot | $28 | $703,85861 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $646 | $240,925289 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.
Other urology in Montebello
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.